Newly Independent Myriad Diagnostics Will Pursue Product Acquisitions
This article was originally published in The Pink Sheet Daily
Executive Summary
Pharmaceutical group to proceed as an independent developer of cancer, infectious disease therapies.
You may also be interested in...
ACOG Guideline Revisions Boost Myriad’s BRCA Test
Pharma-like direct-to-consumer ads should help boost diagnostic’s sales, and AstraZeneca trials could establish use with PARP inhibitors.
ACOG Guideline Revisions Boost Myriad’s BRCA Test
Pharma-like direct-to-consumer ads should help boost diagnostic’s sales, and AstraZeneca trials could establish use with PARP inhibitors.
Strong Abraxane Cancer Data Promised, But Abraxis Mum On Spin-Off Details
Veteran Merck scientist recruited for personalized-medicine push.